Endospan achieves FDA Approval for NEXUS® Aortic Arch Stent Graft System, Expanding Minimally Invasive Options for High-Risk Patients
Endospan, a privately held medical device company based in Tel Aviv, Israel, has reached a significant regulatory milestone with the approval of its NEXUS® Aortic Arch Stent Graft System by the U.S. Food and Drug Administration. This landmark decision marks a major advancement in the treatment of complex aortic arch diseases, particularly for patients who are considered high-risk candidates for traditional open-heart surgery.
The approval not only validates years of research and clinical investigation but also paves the way for the commercial launch of the NEXUS System in the United States. With this development, physicians now have access to a minimally invasive alternative for treating life-threatening conditions affecting the ascending aorta and aortic arch—areas historically difficult to address using endovascular techniques.
Understanding Aortic Arch Disease and Treatment Challenges
Aortic arch disease encompasses a range of serious conditions, including aneurysms and chronic aortic dissections, that affect the upper portion of the aorta. These conditions can be life-threatening due to the risk of rupture or compromised blood flow to vital organs, including the brain.
Each year, more than 120,000 patients across the United States and Europe are affected by thoracic aortic arch disease. Despite this high prevalence, only about 25% of these cases are diagnosed or treated. One of the main reasons for this gap is the complexity of the aortic arch anatomy and the limitations of existing treatment options.
Open surgical repair has long been considered the standard of care for such conditions. However, it is highly invasive and associated with substantial risks, including stroke, mortality, and prolonged recovery times. For patients with significant comorbidities or advanced age, the risks of surgery may outweigh the potential benefits, leaving them with limited or no viable treatment options.
The NEXUS® System: A Purpose-Built Endovascular Solution
The NEXUS® Aortic Arch Stent Graft System represents a new generation of endovascular technology specifically engineered to address the anatomical and clinical challenges of the ascending aorta and aortic arch.
Unlike conventional stent grafts, the NEXUS System features a bimodular design that closely mimics the natural structure of the aorta. This design allows for better alignment and integration within the complex curvature of the arch. Additionally, the system includes an integrated branch component, which enhances hemodynamic performance and ensures adequate blood flow to critical vessels.
One of the standout features of the NEXUS System is its low-profile 20F delivery system, which is among the smallest available for this type of procedure. The system also incorporates a pre-shaped catheter, enabling physicians to navigate the aortic arch in a single pass. This reduces the need for extensive manipulation within the vessel, thereby minimizing the risk of complications such as embolization or vessel injury.
Clinical Validation: The TRIOMPHE IDE Study
The FDA’s approval of the NEXUS System was primarily supported by data from the TRIOMPHE Investigational Device Exemption (IDE) Study. This prospective, multicenter clinical trial was designed to evaluate the safety and effectiveness of the device in patients who were deemed high-risk for conventional open surgery.
The one-year results of the TRIOMPHE study demonstrated that the NEXUS System provided safe and effective treatment for patients with chronic aortic dissections involving the ascending aorta. This segment of the aorta is particularly challenging to treat due to its proximity to the heart and the high-pressure blood flow it experiences.
Importantly, the study showed that the device could achieve favorable outcomes without the high rates of complications typically associated with open surgical repair. These findings underscore the potential of the NEXUS System to transform the treatment paradigm for aortic arch disease.
Expert Perspectives on the Breakthrough
Leading clinicians involved in the TRIOMPHE study have expressed strong support for the NEXUS System and its clinical impact.
Brad Leshnower, the national cardiac surgery co-principal investigator, highlighted the system’s ability to address the complexities of the aortic arch. He noted that the anatomical design of the device enables physicians to treat conditions that were previously difficult or impossible to manage using minimally invasive techniques.
According to Leshnower, the approval allows healthcare providers to offer a new treatment option to patients with life-threatening aortic conditions who are at high risk for open surgery. This represents a meaningful advancement in patient care, particularly for those who previously had limited alternatives.
Similarly, Ross Milner, Chief of the Section of Vascular Surgery and Endovascular Therapy, emphasized the collaborative effort behind the TRIOMPHE study. He acknowledged the contributions of investigators, physicians, and clinical staff who played a crucial role in bringing this technology to fruition.
Expanding Treatment Options for High-Risk Patients
One of the most significant implications of the NEXUS System’s approval is its potential to expand treatment access for high-risk patient populations. Many individuals with aortic arch disease are not candidates for open surgery due to age, frailty, or underlying health conditions.
The introduction of a transcatheter, minimally invasive solution provides a viable alternative for these patients. By reducing the need for large incisions and cardiopulmonary bypass, the NEXUS System offers the possibility of shorter recovery times, fewer complications, and improved overall outcomes.
Moreover, the system’s design addresses the anatomical challenges that have historically limited the use of endovascular techniques in the aortic arch. This opens the door for broader adoption of minimally invasive approaches in a field that has long relied on complex surgical procedures.
Company Leadership and Vision
Endospan’s leadership views the FDA approval as a pivotal moment in the company’s journey. Kevin Mayberry, Chief Executive Officer of Endospan, expressed gratitude to the clinical teams and investigators who contributed to the success of the TRIOMPHE study.
He noted that the NEXUS System was specifically designed to address the unmet needs of patients with ascending and aortic arch disease. The positive clinical data from both the TRIOMPHE study and pre- and post-commercialization experiences in Europe demonstrate the device’s potential as a reliable and effective treatment option.
Mayberry also emphasized the company’s commitment to advancing aortic care and improving patient outcomes through innovative technologies. The U.S. approval represents a major step toward achieving these goals and expanding the reach of the NEXUS System to a broader patient population.
Market Impact and Future Outlook
The FDA approval of the NEXUS® Aortic Arch Stent Graft System is expected to have a significant impact on the field of vascular and endovascular therapy. As the first device of its kind specifically designed for the aortic arch, it fills a critical gap in the current treatment landscape.
With the U.S. commercial launch now underway, Endospan is well-positioned to establish itself as a leader in the endovascular treatment of complex aortic diseases. The company’s innovative approach and strong clinical evidence base are likely to drive adoption among physicians and healthcare institutions.
Looking ahead, continued research and long-term follow-up data will be essential to further validate the safety and effectiveness of the NEXUS System. However, the current evidence and expert endorsements suggest a promising future for this technology.
Conclusion: A New Era in Aortic Arch Treatment
The approval of the NEXUS® Aortic Arch Stent Graft System by the FDA marks a transformative moment in the management of aortic arch disease. By offering a minimally invasive, anatomically tailored solution, Endospan has addressed a longstanding challenge in cardiovascular medicine.
For patients who are unable to undergo open surgery, this innovation provides new hope and expanded treatment possibilities. For clinicians, it represents a powerful tool to improve outcomes and deliver advanced care.
As the NEXUS System enters the U.S. market, it is poised to redefine the standard of care for aortic arch disease and usher in a new era of endovascular therapy.
About Endospan
Privately held Endospan, headquartered in Herzliya (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan’s NEXUS® Aortic Arch Stent-Graft System was the first endovascular off-the-shelf system with CE Mark to treat an underserved group of patients diagnosed with a dilative lesion in, or near, the aortic arch and ascending expanding minimally invasive endovascular repair in this anatomical region. For additional information about Endospan,
